Peptide ReadinessJoin the beta
Back to database

FDA APPROVED COMPARATOR

Teduglutide

A non obesity comparator demonstrating established peptide use in specialist gastroenterology.

Conceptual three-dimensional molecular signature for Teduglutide; not an exact chemical structure.
GLP-2 analogue peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 5 September 2026Evidence grade AAuthorised product precedent
FDA STATUS

FDA approved for a specific product and indication

MHRA / UK LICENCE

UK authorised for a specific product and indication

NICE STATUS

NICE TA804 recommends teduglutide for short bowel syndrome

NHS ACCESS

Specialist NHS access is subject to NICE criteria and commissioning

PRIVATE LAWFUL USE CONTEXT

Lawful use is limited to the licensed specialist indication and appropriate governance

EVIDENCE MATURITY

Authorised evidence in short bowel syndrome

DEVELOPMENT PHASE

Authorised product precedent

MARKET EXPOSURE

Specialist

PROFESSIONAL RELEVANCE

Benchmark specialist service requirements and pathway integration outside the metabolic peptide market.

Product, formulation and indication

Revestive

UK · Injection

Short bowel syndrome

Gattex

US · Injection

Short bowel syndrome

Status history

Production baseline verification recorded.

FDA approved specialist gastrointestinal peptide

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.